Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway

Chemico-Biological Interactions

Volumn 206, Issue 1, 2013, Pages 100-108

  Gao, Ai Mei ^a,c   Ke, Zun Ping ^a   Shi, Fang ^b   Sun, Guang Chun ^a   Chen, Hui ^c  

^a FUDAN UNIVERSITY   (China)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Chemoresistance; Chrysin; Hepatocellular carcinoma; Nrf2

Indexed keywords

ALDOKETOREDUCTASE 1B10; CHRYSIN; DOXORUBICIN; HEME OXYGENASE 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN 5; OXIDOREDUCTASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG SENSITIZATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION;

4′-6′-DIAMIDINO-2-PHENYLINDOLE; ACTIVATING TRANSCRIPTION FACTOR 3; ADM; AKR1B10; ALDO-KETO REDUCTASE 1B10; ATF3; CHEMORESISTANCE; CHRYSIN; DAPI; DOXORUBICIN; EGCG; EPIGALLOCATECHIN 3-GALLATE; ERΑ; ESTROGENRECEPTOR Α; FCM; FLOW CYTOMETRY; HCC; HEME OXYGENASE-1; HEPATOCELLULAR CARCINOMA; HO-1; KEAP1; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; MAPKS; MITOGEN-ACTIVATED PROTEIN KINASES; MRP5; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 5; NRF2; NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR 2; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL-3 KINASE; PI3K; PPAR; QRT-PCR; RARΑ; REAL-TIME QUANTITATIVE PCR; RETINOIC ACID RECEPTOR Α; SFERRΒ; SHORT-FORM ESTROGEN-RELATED RECEPTOR Β;

DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; HUMANS; NF-E2-RELATED FACTOR 2; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84885960813     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2013.08.008     Document Type: Article

References (31)

1. Y.H. Huang, K.H. Lin, H.C. Chen, M.L. Chang, C.W. Hsu, M.W. Lai, T.C. Chen, W.C. Lee, Y.H. Tseng, and C.T. Yeh Identification of postoperative prognostic MicroRNA predictors in hepatocellular carcinoma PLoS One 7 2012 e37188
2. T.W. Kensler, N. Wakabayashi, and S. Biswal Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway Annu. Rev. Pharmacol. Toxicol. 47 2007 89 116
3. K. Shen, D. Cui, L. Sun, M. Han, and J. Liu Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression J. Cell. Biochem. 113 2012 2086 2097
4. C.M. Mahaffey, H. Zhang, A. Rinna, W. Holland, P.C. Mack, and H.J. Forman Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma Free Radical Biol. Med. 46 2009 1650 1657
5. A. Singh, H. Wu, P. Zhang, C. Happel, J. Ma, and S. Biswal Expression of ABCG2 (BCRP), a marker of stem cells, is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype Mol. Cancer Ther. 9 2010 2365 2376
6. S.L. Slocum, and T.W. Kensler Nrf2: control of sensitivity to carcinogens Arch. Toxicol. 85 2011 273 284
7. D.D. Zhang The Nrf2-Keap1-ARE signaling pathway: the regulation and dual function of Nrf2 in cancer Antioxid. Redox Signal. 13 2010 1623 1626
8. N.J. Yoo, H.R. Kim, Y.R. Kim, C.H. An, and S.H. Lee Somatic mutations of the KEAP1 gene in common solid cancers Histopathology 60 2012 943 952
9. T. Suzuki, J. Maher, and M. Yamamoto Select heterozygous Keap1 mutations have a dominant-negative effect on wild-type Keap1 in vivo Cancer Res. 71 2011 1700 1709
10. L.A. Muscarella, P. Parrella, V. D'Alessandro, A. la Torre, R. Barbano, A. Fontana, A. Tancredi, V. Guarnieri, T. Balsamo, M. Coco, M. Copetti, F. Pellegrini, P. De Bonis, M. Bisceglia, G. Scaramuzzi, E. Maiello, V.M. Valori, G. Merla, G. Vendemiale, and V.M. Fazio Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer Epigenetics 6 2011 710 719
11. S. Magesh, Y. Chen, and L. Hu Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents Med. Res. Rev. 32 2012 687 726
12. L. Zhong, H. Shen, C. Huang, H. Jing, and D. Cao AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group Toxicol. Appl. Pharmacol. 255 2011 40 47
13. M.D. Bacolod, S.M. Lin, S.P. Johnson, N.S. Bullock, M. Colvin, D.D. Bigner, and H.S. Friedman The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide Curr. Cancer Drug Targets 8 2008 172 179 (Pubitemid 351666854)
14. A. Khadir, J. Verreault, and D.A. Averill Inhibition of antioxidants and hyperthermia enhance bleomycin-induced cytotoxicity and lipid peroxidation in Chinese hamster ovary cells Arch. Biochem. Biophys. 370 1999 163 175 (Pubitemid 29491421)
15. J. Alexandre, Y. Hu, W. Lu, H. Pelicano, and P. Huang Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species Cancer Res. 67 2007 3512 3517 (Pubitemid 46762129)
16. T. Matsunaga, Y. Wada, S. Endo, M. Soda, O. El-Kabbani, and A. Hara Aldo-keto reductase 1B10 and its role in proliferation capacity of drug-resistant cancers Front. Pharmacol. 3 2012 5
17. X.B. Wang, S.S. Wang, Q.F. Zhang, M. Liu, H.L. Li, Y. Liu, J.N. Wang, F. Zheng, L.Y. Guo, and J.Z. Xiang Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3and MRP5 in multidrug resistant human hepatocellular carcinoma cells Oncol. Rep. 23 2010 211 215
18. P.K. Nambaru, T. Hübner, K. Köck, S. Mews, M. Grube, L. Payen, J. Guitton, M. Sendler, G. Jedlitschky, C. Rimmbach, D. Rosskopf, D.W. Kowalczyk, H.K. Kroemer, F.U. Weiss, J. Mayerle, M.M. Lerch, and C.A. Ritter Drug efflux transporter multidrug resistance associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil Drug Metab. Dispos. 39 2011 132 139
19. H. Sui, S. Zhou, Y. Wang, X. Liu, L. Zhou, P. Yin, Z. Fan, and Q. Li COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer Carcinogenesis 32 2011 667 675
20. H. Shen, W. Xu, W. Luo, L. Zhou, W. Yong, F. Chen, C. Wu, Q. Chen, and X. Han Upregulation of mdr1 gene is related to activation of the MAPK/ERK signal transduction pathway and YB-1 nuclear translocation in B-cell lymphoma Exp. Hematol. 39 2011 558 569
21. X. Guo, N. Ma, J. Wang, J. Song, X. Bu, Y. Cheng, K. Sun, H. Xiong, G. Jiang, B. Zhang, M. Wu, and L. Wei Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancercells BMC Cancer 8 2008 375
22. C. Kandaswami, L.T. Lee, P.P. Lee, J.J. Hwang, F.C. Ke, Y.T. Huang, and M.T. Lee The antitumor activities of flavonoids In Vivo 19 2005 895 909
23. A. Angelini, C. Di Ilio, M.L. Castellani, P. Conti, and F. Cuccurullo Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin-resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy J. Biol. Regul. Homeost. Agents 24 2010 197 205
24. M.H. Kweon, V.M. Adhami, J.S. Lee, and H. Mukhtar Constitutive overexpression of Nrf2 dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate J. Biol. Chem. 281 2006 3361 3372
25. X. Tang, H. Wang, L. Fan, X. Wu, A. Xin, H. Ren, and X.J. Wang Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs Free Radical Biol. Med. 50 2011 1599 1609
26. D. Ren, N.F. Villeneuve, T. Jiang, T. Wu, A. Lau, H.A. Toppin, and D.D. Zhang Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediateddefense mechanism Proc. Natl. Acad. Sci. USA 108 2011 1433 1438
27. X.M. Yu, T. Phan, P.N. Patel, R. Jaskula-Sztul, and H. Chen Chrysin activates Notch1 signaling and suppresses tumor growth of anaplastic thyroidcarcinoma in vitro and in vivo Cancer 18 2012 doi: 10.1002/cncr.27742. [Epub ahead of print]
28. P. Zhang, A. Singh, S. Yegnasubramanian, D. Esopi, P. Kombairaju, M. Bodas, H. Wu, S.G. Bova, and S. Biswal Loss of Kelch like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth Mol. Cancer Ther. 9 2010 336 346
29. J.J. Shao, A.P. Zhang, W. Qin, L. Zheng, Y.F. Zhu, and X. Chen AMP-activated protein kinase (AMPK) activation is involved in chrysin-induced growth inhibition and apoptosis in cultured A549 lung cancer cells Biochem. Biophys. Res. Commun. 423 2012 448 453
30. C.R. Zhao, Z.H. Gao, and X.J. Qu Nrf2-ARE signaling pathway and natural products for cancer chemoprevention Cancer Epidemiol. 34 2010 523 533
31. J.D. Hayes, and M. McMahon NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer Trends Biochem. Sci. 34 2009 176 188.